Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
October 31, 2016
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
Conditions
Healthy Subjects, Overactive Bladder
Interventions
DRUG
Formulation 1 solabegron
DRUG
Formulation 2 solabegron
All Listed Sponsors
lead
Velicept Therapeutics, Inc.
INDUSTRY
NCT02938507 - Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects | Biotech Hunter | Biotech Hunter